Tyler Technologies ( TYL ) priced an upsized private offering of $1.25B aggregate principal amount of 0.50% convertible senior notes due 2031. The initial purchasers of the notes have an option to purchase up to an additional $187.5M notes. The offering size was increased from the previously announced offering size of $1B. The net proceeds will be used to fund capped call transactions and ~$320.7M...
Tyler Technologies ( TYL ) priced an upsized private offering of $1.25B aggregate principal amount of 0.50% convertible senior notes due 2031. The initial purchasers of the notes have an option to purchase up to an additional $187.5M notes. The offering size was increased from the previously announced offering size of $1B. The net proceeds will be used to fund capped call transactions and ~$320.7M to repurchase about 1.03M shares of common stock in privately negotiated transactions. The remaining proceeds will be used for general corporate purposes. The notes will be senior unsecured debt and will carry an annual interest rate of 0.50%, payable twice a year starting Jan. 15, 2027. The issuance and sale of the notes are scheduled to settle on May 14, 2026. More on Tyler Technologies Tyler Technologies: Can't Get Behind The Valuation Despite The Selloff Tyler Technologies: Encouraging Recovery In Bookings (Rating Upgrade) Tyler Technologies, Inc. (TYL) Q1 2026 Earnings Call Transcript Tyler Technologies plans $1B convertible senior notes offering due 2031 Tyler targets 80%+ of on-prem customers moved to the cloud by 2030 as For The Record adds ~$30M to 2026 revenue guide
Strong corporate earnings are currently outweighing geopolitical concerns in financial markets despite tensions between the US and Iran, according to JPMorgan Chase & Co. ’s Dubravko Lakos-Bujas . The firm’s head of global markets strategy noted that markets entered the current energy shock with relatively healthy inventories, which has helped cushion the impact of supply disruptions. Meanwhile, t...
Strong corporate earnings are currently outweighing geopolitical concerns in financial markets despite tensions between the US and Iran, according to JPMorgan Chase & Co. ’s Dubravko Lakos-Bujas . The firm’s head of global markets strategy noted that markets entered the current energy shock with relatively healthy inventories, which has helped cushion the impact of supply disruptions. Meanwhile, the earnings narrative is providing a strong counterpoint to the geopolitical tensions, with Lakos-Bujas describing recent corporate results as “blockbuster” and “extremely strong.” While he’s “less worried about fundamentals,” he pointed to risks around “excessive crowding that could cause flash crashes” in momentum stocks that have risen aggressively. “I think earnings, the AI narrative has been overriding the whole geopolitical oil situation. Now obviously, if you fast forward another four or five weeks and the situation remains unresolved, then you get complacency,” he told Bloomberg Television in an interview. Looking ahead, the head strategist identified two major global shortages affecting markets: physical oil shortages, and computing chip shortages affecting the AI sector. He noted central banks have been removing the easing bias that prevailed late last year, with some now discussing potential rate hikes. On the AI front, Lakos-Bujas expressed confidence in US competitiveness despite China’s progress, suggesting “there is space for both of them” in the evolving technology landscape. He indicated that concerns about AI monetization would likely become more relevant beyond the next six to 12 months. This story was produced with the assistance of Bloomberg Automation.
An American climber has died in an avalanche on Mount Makalu, officials said on Tuesday, as fatalities mount early in Nepal’s busy spring climbing season. Shelley Johannesen, 53, was killed on Monday while descending from the summit of the world’s fifth-highest peak, expedition organisers said, marking the season’s latest death. David Roubinek, a 38-year-old Czech climber, and three Nepali guides ...
An American climber has died in an avalanche on Mount Makalu, officials said on Tuesday, as fatalities mount early in Nepal’s busy spring climbing season. Shelley Johannesen, 53, was killed on Monday while descending from the summit of the world’s fifth-highest peak, expedition organisers said, marking the season’s latest death. David Roubinek, a 38-year-old Czech climber, and three Nepali guides have died in the Himalayas so far this season. Johannesen, co-founder of US-based outfitter Dash...
Amanda Lynam, chief credit strategist at Goldman Sachs, says the scale of investment in artificial intelligence is forcing corporates to increasingly diversify their funding outside the US. She speaks on Bloomberg Television. (Source: Bloomberg)
Amanda Lynam, chief credit strategist at Goldman Sachs, says the scale of investment in artificial intelligence is forcing corporates to increasingly diversify their funding outside the US. She speaks on Bloomberg Television. (Source: Bloomberg)
wildpixel/iStock via Getty Images Liquidia Overview Liquidia's ( LQDA ) first-quarter earnings report looks like everything bulls were hoping for. Yutrepia's net product sales were up 44% sequentially, the business recorded its third consecutive quarter of profitability, and its pipeline is advancing as expected. In my last analysis, in March, I upgraded LQDA to Hold. Although I had been bearish o...
wildpixel/iStock via Getty Images Liquidia Overview Liquidia's ( LQDA ) first-quarter earnings report looks like everything bulls were hoping for. Yutrepia's net product sales were up 44% sequentially, the business recorded its third consecutive quarter of profitability, and its pipeline is advancing as expected. In my last analysis, in March, I upgraded LQDA to Hold. Although I had been bearish on the name in the past (read my January Sell analysis), Yutrepia’s initial commercial numbers demanded a change of heart. While I've become increasingly optimistic on Liquidia's short-term prospects, I’ve remained cautious on the long-term trajectory for multiple reasons. Due to limited product differentiation, I posited that Yutrepia’s market share gains were capped by patient preferences and established players. Moreover, I noted some major competitive risks that are on the horizon, such as United Therapeutics’ ( UTHR ) Tresmi (a soft mist inhaler, planned NDA submission later this year) and Ralinepag (an oral, once-daily prostacyclin, planned NDA submission later this year). And don't forget about Insmed’s ( INSM ) once-daily TPIP (Phase 3). Now, Liquidia does have plans to address, or strengthen, its competitive moat, including a twice-daily nebulizer (arguably a step backward on device convenience vs. DPIs), L606, but I thought that this late-stage prospect offers, at best, only incremental convenience advantages. And L606 also faces less favorable economics than Yutrepia due to royalty obligations. With LQDA up over 20% in intraday trading (at writing) and its market capitalization inching closer to $5 billion, I wanted to do a deep dive on the hidden implications of Liquidia's first-quarter results. Data by YCharts My analysis reveals that Liquidia’s valuation may now imply that the market is becoming too short-sighted. Recent Developments I'm only going to briefly cover the numbers because they're clearly listed there in the earnings report. Liquidia beat consensus ...